China’s First Fully Self-Developed Robotic Arm for Orthopedic Surgery Launches Amid Active Trading of Medical Innovation ETF

China’s First Fully Self-Developed Robotic Arm for Orthopedic Surgery Begins Operations, Medical Innovation ETF (516820) Trades Actively

As of February 12, 2026, at 10:16 AM, the CSI Medical and Medical Device Innovation Index (931484) rose by 0.05%. Notable component stocks include WuXi AppTec, which increased by 3.39%, CanSino Biologics by 1.37%, Huitai Medical by 0.27%, Enhua Pharmaceutical by 0.25%, and Teva Biologicals by 0.14%. The Medical Innovation ETF (516820) is currently priced at 0.37 yuan. In terms of liquidity, the ETF saw a turnover rate of 0.42% during the day, with a total transaction volume of 7.944 million yuan. Over a longer period, the average daily transaction volume of the ETF for the past month reached 65.1423 million yuan as of February 11.

On February 11, the first fully self-developed HX robotic arm for orthopedic surgery in China made its debut. Professor Zhou Zongke, Director of the Orthopedics Department at Sichuan University West China Hospital, led a team to successfully perform a robot-assisted total knee replacement on a 66-year-old woman using the HX robotic arm.

CITIC Securities views surgical robots as one of the best business models in the medical device sector. Once installed, these devices will drive a continuous increase in consumables, creating stable revenue and cash flow. The global benchmark leader, Intuitive Surgical, has surpassed a market value of 1 trillion yuan, with substantial room for growth in penetration rates and market size. While international leaders hold dominant market positions due to first-mover advantages, domestic leaders are rapidly advancing product iterations, with performance nearing global levels. They are also leading in remote surgery, with overseas operations accounting for a significant portion of their revenue and showing sustained high growth, indicating multiple times growth potential in both revenue and market value.

Artificial Intelligence is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing parts of the surgical process typically performed by doctors, which could enhance industry penetration and improve the valuations of related companies.

The Medical Innovation ETF closely tracks the CSI Medical and Medical Device Innovation Index. This index selects 30 publicly listed companies from the healthcare sector that have good profitability, growth potential, and research and development capabilities to reflect the overall performance of profitable and growing medical and medical device companies. As of January 30, 2026, the top ten weighted stocks in the index are WuXi AppTec, Mindray Medical, Hengrui Medicine, Aier Eye Hospital, Pien Tze Huang, New Horizon Health, East China Pharmaceutical, CanSino Biologics, Ailisi, and Ganli Pharmaceutical. Together, these top ten stocks account for 63.9% of the index.

Risk Warning: Investing in funds carries risks, and caution is advised. The fund manager commits to managing and utilizing fund assets with honesty and diligence but cannot guarantee profits or minimum returns. Investors should be aware that they bear the risk associated with changes in fund operations and net asset values after making investment decisions. Past performance and net asset values do not predict future results, and the performance of other funds managed by the same manager does not guarantee this fund’s performance. Investors may share in the profits generated by the fund in proportion to their holdings but may also incur losses from fund investments. It is essential to read the Fund Contract and Prospectus carefully to understand the risk-return characteristics and product features of the fund and to evaluate whether it aligns with their risk tolerance based on their investment objectives, duration, experience, and asset status. The information provided here is sourced from publicly available materials deemed reliable by the fund manager, and the opinions, assessments, and forecasts reflect current judgments that may change in the future. Any market views expressed are based on specific assumptions, which may also change at any time. The fund manager does not guarantee that any predictive market views will be realized. The individual stocks mentioned do not constitute investment recommendations.

The secondary market fluctuations of the ETF do not represent the actual yield of the fund, so investors should pay attention to the risks associated with price volatility. Unauthorized reproduction of this material is strictly prohibited and will be pursued. For permissions, please contact: youlianyunpindao@163.com. The above content and data are for reference only and do not constitute investment advice; please verify before use. Any actions taken based on this material are at the investor’s own risk.